Search research articles
Contact Us
Filters
Showing results (51-60 of 61) with videos related to
Page
of 7
Sort By:
Lancet (London, England)
|
May 15, 2022
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial
Alan Pollack, Theodore G Karrison, Alexander G Balogh, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 4, 2020
COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19
Garth W Strohbehn, Brian L Heiss, Sherin J Rouhani, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 25, 2024
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377
Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2021
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors
Corey C Foster, Gini F Fleming, Theodore G Karrison, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 8, 2022
The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521
William A Hall, Theodore G Karrison, Seth A Rosenthal, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 3, 2023
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial
Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
European Urology
|
June 26, 2025
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data
Sarah Burdett, David J Fisher, Jayne F Tierney, et al.
Clinical Pharmacology and Therapeutics
|
November 19, 2020
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia
Garth W Strohbehn, Brian L Heiss, Sherin J Rouhani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2023
Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial
Benjamin Movsas, Joseph P Rodgers, Mohamed A Elshaikh, et al.
Blood Advances
|
February 10, 2025
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia
Athalia R Pyzer, Laura W Dillon, Elad Sharon, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 61) with videos related to
Sort By:
Page
of 7
Lancet (London, England)
|
May 15, 2022
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial
Alan Pollack, Theodore G Karrison, Alexander G Balogh, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 4, 2020
COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19
Garth W Strohbehn, Brian L Heiss, Sherin J Rouhani, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 25, 2024
Erratum to: Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJS, Parliament MB, Dayes IS, Correa RJM, Robertson JM, Gore EM, Doncals DE, Vigneault E, Souhami L, Karrison TG, Feng FY. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370-377
Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2021
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors
Corey C Foster, Gini F Fleming, Theodore G Karrison, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 8, 2022
The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521
William A Hall, Theodore G Karrison, Seth A Rosenthal, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 3, 2023
Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial
Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, et al.
European Urology
|
June 26, 2025
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data
Sarah Burdett, David J Fisher, Jayne F Tierney, et al.
Clinical Pharmacology and Therapeutics
|
November 19, 2020
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia
Garth W Strohbehn, Brian L Heiss, Sherin J Rouhani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2023
Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial
Benjamin Movsas, Joseph P Rodgers, Mohamed A Elshaikh, et al.
Blood Advances
|
February 10, 2025
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia
Athalia R Pyzer, Laura W Dillon, Elad Sharon, et al.
Page
of 7